tradingwizard

@Shashank1171 Not everything that's going up is a AI-generated content bull story. Respected you in the past, but of late, your content quality has degraded with posting bull story with everything that's going up using AI slop.

Live example of why price action is not always right. Highlights the risk of investing in a company where catalyst is 'speculative' not real. Only way to play such stocks is, minimal allocation when a catalyst is speculative and increase only when catalyst plays out as expected. #RAMCOSYS

@SureshKBN IDFC bank results also point to microfin recovery.

Every good result gets my full attention .. I’ve said that a hundred times. What most people seriously lack is not knowledge, but seriousness, discipline and consistency. I consider myself a reasonably successful investor, yet I still read, learn and study every single day. Success does not reduce the need for effort. It increases the responsibility to stay sharp.

@Normal_2610 The next one to do this in the next few years would be WockPharma.

Judging deep tech pharma on quarterly numbers misses what matters. Revenue timing, regulatory approvals, and customer schedules move on clocks management cannot control. What they can control is reactor capacity, physical vessels where chemical reactions happen at scale. Laurus spent years building over 8200 KL of reactor volume while ROCE, profit per rupee of capital invested, sat in single digits. Those choices later produced 67% growth in CDMO revenue, money earned manufacturing drugs on contract for global pharma, and operating margins of 31.8% Approx. i think :) When margins drop, the crowd treats every capital outlay as proof of bad judgment That pattern ignored years of building specialized lines for peptides, short chains of amino acids used in new drugs, and fermentation, where living cells produce biological compounds at scale. These platforms quietly converted into commercial supply contracts. Manufacturing skill compounds over years before profit numbers reflect it. Focusing only on lagging numbers hands the edge to patient investors - this is classic case study Shifting from next quarter guidance to what a business can become in 10 years changes the entire decision filter. Instead of demanding exact launch dates, the useful work is understanding how capital gets steered into new process technologies. In pharma contract manufacturing, clinical delays and customer rescheduling are normal features of how the industry works, not signs of management failure like if yu watch out Neuland the lympiness in it Laurus lifting ROCE, profit per rupee of capital invested, from 6% to over 18% in 3 years confirms that earlier capability bets were right even when published numbers looked poor

@PadikuChalak @Leo04G @Beatnik_BaBa These kind of stocks are not valued on PE, but EV/EBIDTA. Check the ratio and you would find it undervalued compared to global peers.

@Leo04G @Beatnik_BaBa E2E is great business and promotors but you are paying 9600 market cap for 350 cr sales and 30 cr profit. Yes it is fast growing but everything is priced in at the moment

Leo's Stock Space | No politics x.com/i/spaces/1YGNr…

@SureshKBN Portfolio automatically getting filled with these. Added Satin first after Q1 update, then Jana after Q1 result, added Suryodyay today. These three constitute 40%+ os portfolio now.

see ujjivan , suryoday , later satin and many more .. what u r reading

@VCPSwing Would you have traded Cleanmax 3-4 days back the same way you traded FCL or Azad?

With time, these water names are only getting more interesting. The flags just keep getting tighter and more constructive. I'm keeping margin reserved in the portfolio for them. If they trigger, I want to be ready ,not chasing after the move. #WABAG #DENTA #EIEL

#WABAG continues to lead with both technicals and catalysts #DENTA and #EIEL are also respecting the 10/20 MA and showing constructive price action. The common thread across all three: • Strong prior buying pressure. • Shallow, controlled retracement. • All bouncing on the same day. These are the characteristics to look for when scanning for high-quality continuation candidates

@SureshKBN Check Jana Small Finance Bank as well. It posted great results and management was very confident in the call about the future. Trading at 1.1-1.2 times FY 27 PB

Ujjivan 😀.. if oil comes down others will follow rapidly

@Fastzonetrader Hope supply was absorbed the next day of your tweet 🤣

@Fastzonetrader See FCL now.

Prime examples of supply not absorbed fully 👇 #fcl #netweb #jnkindia Just because someone posted on x ,doesn’t mean it will work .Trust & understand price action then take trades. No trades taken today on burst side Only holding #behl & #inoxindia (1.2% open gains)

@inv_vin8 Had been following MPS since last quarter result. Since I am a technofunda investor, momentum wasn’t convincing yet. But on this quarter’s result, I entered yesterday. Concall was as bullish as it can get.

Hubris is our greatest enemy. It consumes ourselves. Can’t blame much but should beat myself up for missing this opportunity. Mps was a clean slate bet, offered like a platter. Pathetic miss. Wonderful Concall !!

@_HealthZwealth Check Gem Aromatics

@SureshKBN Bought it at 392, sold at 520 thinking it moved too fast. Should have held longer.

how everyone gone wrong with kalyan jeweles ?. all gave lectures r wrote threads on it :)

@Salman_2911 Strip out depreciation as well then, no? Other income and depreretiaction alomost cancel earch other out.

Paytm Q1 FY27. Everyone's calling it a turnaround. Half right. Revenue ₹2,448 Cr, +28% YoY. EBITDA ₹203 Cr vs ₹72 Cr. PAT ₹220 Cr. Fifth straight profitable quarter 📈 Now the part nobody is tweeting. Other income was ₹182 Cr. Strip it out and core PBT is ₹65 Cr. The ₹13,529 Cr cash pile is doing most of the heavy lifting on the bottom line. And it's already down 24% YoY as repo cuts bite. The operating story is still real though. Indirect costs grew 6% against revenue at 28%. Comparable EBITDA went ₹18 Cr to ₹195 Cr. That gap is the entire thesis. The catch nobody wants to discuss. Contribution margin 60% → 55%. Growth is being bought, not given. Board also said no to the bonus issue. Instead asked to hold ₹1,686 Cr of unspent IPO money till 2029. At ₹86,000 Cr mcap you're paying for FY29, not FY27. Turnaround, yes. Compounding, not yet #PAYTM Stay not out. Not an investment advice. DYOR

@SureshKBN Fineotex chem falls in this bracket aftet the PEAD of last quarter

My view of PEAD is simple: price action should sustain even after the next quarter. I can give countless examples Lumax Auto, Bajaj Consumer, STL Tech and HFCL are the first that come to mind. I am not interested in PEAD for a 10–15% price target. That is simply not worth my time. I look for businesses where one strong quarter starts a much bigger earnings and price trend.

@SureshKBN Seems like Jana SFB could be a PEAD candidate. 70%+ secured loan book, 80% plus PAT guidance, credit costs going down, RoA is improving.

See most imp is q1 commentary and h2Fy27 results

@SureshKBN @callme_kirangk Deep research mode in Gemini with extended complex reasoning selection generally gives such a detailed view into most companies irrespective of the size of the company.

@callme_kirangk why where from u get all this companies less than 1000 cr ?

#Textile 𝗧𝗵𝗲 𝗨𝗞 𝘄𝗲𝘁 𝘄𝗶𝗽𝗲𝘀 𝗯𝗮𝗻 𝗰𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗨𝗞-𝗜𝗻𝗱𝗶𝗮 𝗙𝗿𝗲𝗲 𝗧𝗿𝗮𝗱𝗲 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 (𝗙𝗧𝗔) 𝗰𝗿𝗲𝗮𝘁𝗲𝘀 𝗮𝗻 𝘂𝗻𝗽𝗿𝗲𝗰𝗲𝗱𝗲𝗻𝘁𝗲𝗱 𝗱𝘂𝗮𝗹-𝗴𝗿𝗼𝘄𝘁𝗵 𝗲𝗻𝗴𝗶𝗻𝗲 𝗳𝗼𝗿 𝘁𝗵𝗶𝘀 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 The UK is banning the sale and supply of single-use wet wipes containing plastic. The legislation targets microplastic pollution and sewage blockages (fatbergs).Implementation dates vary by nation: Wales: December 18, 2026 England & Northern Ireland: May 19, 2027 Scotland: August 11, 2027 Ginni Filaments Limited has sold its spinning, knitting and processing units (plants in Mathura and Chatha) of its old/traditional textile division to RSWM Limited for ₹160 crore (Slump Sale) . The sale was completed in 2024 itself. So, at present, the company does not have the old traditional bulk yarn or fabric production divisions. After these changes, the company has completely shifted towards Technical Textiles and Consumer Products. In this context, let us now clearly see how the UK FTA will benefit the Ginni Filaments Company: 1. Duty free on non-woven fabric rolls (Technical Textiles) Although the company sells conventional yarn, it is also manufacturing non-woven spunlace fabric rolls in bulk at its Panoli plant in Gujarat. As part of the UK FTA, import duties ranging from 8% to 12% on roll goods (Roll Goods / Raw Material for Wipes) falling under the technical textiles category have been abolished .Local brands in the UK import these non-woven rolls, which they need to make wet wipes or cosmetics, duty-free from Ginni Filaments. 2. Noida Plant and Cosmetic Garments/Wipes Converting Although the company sold its traditional spinning unit, it retained its Consumer Products Division (CPD) in Noida and Haridwar. Here they manufacture not only wet wipes, but also advanced products such as medical wound care, surgical products, and cosmetic pads.Under FTA rules, medical textiles (medical disposables) that fall under "integrated technical textiles" are eligible for tax exemptions in the UK. 3. Recent major expansion (May 2026 Board Approval)With the money raised from the sale of the traditional business, the company has embarked on a new expansion towards technical textiles with an investment of Rs. 132 crore, Rs. 94 crore For setting up a new spunlace non-woven line with a capacity of 10,000 metric tonnes in Panoli. Rs. 15 crore For expansion of cosmetics division in Haridwar (800 MT). Rs. 10 crore To increase capacity of medical products and kitchen rolls. The ongoing ₹132 crore Capex (approved in May 2026) is expected to drive the next leg of growth once it becomes operational between late 2026 and mid-2027 Top-line Growth (Revenue): For FY26, the company reported a standalone operational revenue of ₹368.70 crores. With the Panoli plant’s Spunlace non-woven capacity expanding by an additional 10,000 MT (nearly doubling current capacity), analysts project the company's annual revenue to clear the ₹500 to ₹550 crore mark by FY28 (2027-28). Operating Margin Expansion (OPM %): The traditional spinning business historically dragged down margins. The pivot toward high-value technical fabrics, cosmetics (expanding from 200 MT to 800 MT), and medical disposables is expected to push Operating Profit Margins (OPM) from the current ~14.7% into the 16% – 18% range. Debt Optimization: The cash proceeds from the older asset sales have enhanced the internal accruals, keeping the debt-to-equity ratio under healthy limits even with the fresh bank term loans taken for the expansion. Sorry to tag you directly @SureshKBN sir

@simrat11exp Goodluck

Whenever I have read concalls of precision tubes maker which is now making artillery shells, I have come back with more questions than answers. One of the rare companies where things never stop looking hazy.

@ItsVinay01 If I had to play the sector, I would only focus on three - EFFWA, Wabag and Ion Exchange. They are the only ones with a moat; the rest are EPC contractors with government orders.

What is your analysis on Water Treatment related companies ? They are getting good order books and have good visibility for next few years. But they are not very cheap as they are already been discovered in last bull market. The growth rate in most of the companies will be good but mostly in compounder category and not high growth curve. So, trading them has to be adjusted accordingly as traders mostly look for short term quick bursts. Try to go with ones where growth rate can be high at least for now. what are your thoughts ?

@SureshKBN Satin also posted a similar update a couple of days ago

What stands out in Muthoot Microfin’s Q1 update is not just 18% AUM growth. Disbursements +49% YoY, collection efficiency at 97.97%, X-bucket CE at 99.89%, and non-JLG mix rising from 17% to 24%. Growth is returning, asset quality is improving, and diversification is accelerating the right combination for an earnings recovery.

@Breakout_trades Jewellery

New leaders may emerge